OncoMatch/Clinical Trials/NCT07645261
SBRT-LATTICE-PATHY
Is NCT07645261 recruiting? Yes, currently enrolling (Jul 2026). This Phase 2 trial studies non-drug interventions for cancer (advanced stage).
To assess the importance of using SBRT-LATTICE-PATHY for the radiotherapy treatment of large tumors that would be considered intractable by currently used standard techniques. In this present study, the investigators will have the possibility of combining SBRT and LATTICE techniques, incorporating the concept of hypoxic tissue irradiation, which are potential modulators of abscopal and bystander effects, performing partial punctual treatment in the vertex region, without the need for irradiation of the entire tissue volume, further improving safety in relation to possible toxicities.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: local radiotherapy
previous local radiotherapy
Cannot have received: systemic therapy
ongoing systemic therapy
Lab requirements
Kidney function
renal insufficiency that prevents the use of iodinated contrast [excluded]
renal insufficiency that prevents the use of iodinated contrast [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07645261 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior local radiotherapy, systemic therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify